Director at Alterity (NASDAQ: ATHE) receives 2M options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Babarczy Julian Michael
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Unlisted option exp 15 Jun 2031 | 2,000,000 | $0.00 | -- |
Holdings After Transaction:
Unlisted option exp 15 Jun 2031 — 2,000,000 shares (Indirect, Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>)
Footnotes (1)
Key Figures
Options granted: 2,000,000 options
Exercise price: 1.0000 per share
Expiration date: June 15, 2031
+2 more
5 metrics
Options granted
2,000,000 options
Grant of unlisted options on June 15, 2026
Exercise price
1.0000 per share
Exercise price for each option
Expiration date
June 15, 2031
Option term end date
Underlying shares
2,000,000 ordinary shares
Shares issuable upon option exercise
Options after transaction
2,000,000 options
Total derivative holdings following grant
Key Terms
Unlisted option, exercise price, expiration date, indirect ownership, +1 more
5 terms
Unlisted option financial
"Unlisted option exp 15 Jun 2031"
exercise price financial
"conversion_or_exercise_price: "1.0000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2031-06-15T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
indirect ownership financial
"ownership_type: "indirect", ownership_code: "I""
derivative securities financial
"transaction_type: "derivative""
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
What did Alterity Therapeutics (ATHE) disclose in this Form 4 filing?
Alterity Therapeutics reported that director Julian Michael Babarczy received 2,000,000 unlisted options as a compensation-related grant. These options are exercisable into ordinary shares and were awarded through an associated investment entity rather than via open-market share purchases or sales.
How many options were granted to the Alterity Therapeutics (ATHE) director?
The director was granted 2,000,000 unlisted options linked to Alterity Therapeutics ordinary shares. Each option represents the right to acquire one share, increasing his indirect derivative position to 2,000,000 options following this award, according to the reported post-transaction holdings.
What is the exercise price and term of the new ATHE options grant?
The newly granted options have an exercise price of 1.0000 per share and expire on June 15, 2031. This gives the holder a multi‑year window to decide whether to convert the options into Alterity Therapeutics ordinary shares at that fixed price.
Is the Alterity Therapeutics (ATHE) Form 4 transaction an open-market trade?
No, the Form 4 shows a grant or award acquisition of derivative securities, not an open-market stock trade. The 2,000,000 unlisted options were awarded as compensation and are held indirectly through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>.
How are the ATHE options held by director Julian Babarczy structured?
The 2,000,000 unlisted options are reported as indirectly owned through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>. This structure means the options are held via an associated investment account rather than directly in the director’s personal name.